ALNY vs. TEVA
ALNY (Alnylam Pharmaceuticals, Inc.) and TEVA (Teva Pharmaceutical Industries Limited) are both stocks. Both are in the Healthcare sector — ALNY in Biotechnology, TEVA in Drug Manufacturers - Specialty & Generic. Over the past 10 years, ALNY returned 16.55%/yr vs -4.15%/yr for TEVA. At a 0.26 correlation, their price movements are largely independent.
Performance
ALNY vs. TEVA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ALNY achieves a -26.53% return, which is significantly lower than TEVA's 6.57% return. Over the past 10 years, ALNY has outperformed TEVA with an annualized return of 16.55%, while TEVA has yielded a comparatively lower -4.15% annualized return.
ALNY
- 1D
- -3.59%
- 1M
- -0.98%
- YTD
- -26.53%
- 6M
- -32.06%
- 1Y
- -2.88%
- 3Y*
- 15.25%
- 5Y*
- 13.17%
- 10Y*
- 16.55%
TEVA
- 1D
- -2.72%
- 1M
- -6.91%
- YTD
- 6.57%
- 6M
- 17.40%
- 1Y
- 87.17%
- 3Y*
- 65.55%
- 5Y*
- 25.39%
- 10Y*
- -4.15%
ALNY vs. TEVA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals, Inc. | -26.53% | 68.99% | 22.94% | -19.46% | 40.14% | 30.48% | 12.85% | 57.96% | -42.61% | 239.34% |
TEVA Teva Pharmaceutical Industries Limited | 6.57% | 41.61% | 111.11% | 14.47% | 13.86% | -16.99% | -1.53% | -36.45% | -18.63% | -46.18% |
Correlation
The correlation between ALNY and TEVA is 0.38, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.38 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.27 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Jun 2, 2004 | 0.26 |
The correlation between ALNY and TEVA shifts across timeframes, from 0.26 (5 years) to 0.38 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
ALNY:
$40.38B
TEVA:
$39.21B
ALNY:
$4.26
TEVA:
$1.34
ALNY:
68.52
TEVA:
24.87
ALNY:
9.23
TEVA:
2.24
ALNY:
37.55
TEVA:
4.76
ALNY:
$4.29B
TEVA:
$17.35B
ALNY:
$2.51B
TEVA:
$9.03B
ALNY:
$729.86M
TEVA:
$3.05B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ALNY vs. TEVA — Risk / Return Rank
ALNY
TEVA
ALNY vs. TEVA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and Teva Pharmaceutical Industries Limited (TEVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ALNY | TEVA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.33 | ||
| Sortino ratioReturn per unit of downside risk | -3.27 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.43 | -0.42 |
| Calmar ratioReturn relative to maximum drawdown | -0.07 | 4.02 | -4.09 |
| Martin ratioReturn relative to average drawdown | -0.12 | 10.94 | -11.06 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ALNY | TEVA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.08 | 2.25 | -2.33 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.27 | 0.59 | -0.32 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.31 | -0.09 | +0.40 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.32 | 0.31 | +0.01 |
Drawdowns
ALNY vs. TEVA - Drawdown Comparison
The maximum ALNY drawdown since its inception was -83.58%, smaller than the maximum TEVA drawdown of -90.89%. Use the drawdown chart below to compare losses from any high point for ALNY and TEVA.
Loading charts...
Drawdown Indicators
| ALNY | TEVA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.58% | -90.89% | +7.31% |
Max Drawdown (1Y)Largest decline over 1 year | -42.01% | -21.79% | -20.22% |
Max Drawdown (3Y)Largest decline over 3 years | -42.01% | -43.70% | +1.69% |
Max Drawdown (5Y)Largest decline over 5 years | -42.46% | -43.70% | +1.24% |
Max Drawdown (10Y)Largest decline over 10 years | -59.95% | -88.41% | +28.46% |
Current DrawdownCurrent decline from peak | -40.52% | -50.84% | +10.32% |
Average DrawdownAverage peak-to-trough decline | -30.59% | -32.00% | +1.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.22% | 8.00% | +15.22% |
Volatility
ALNY vs. TEVA - Volatility Comparison
Alnylam Pharmaceuticals, Inc. (ALNY) has a higher volatility of 9.94% compared to Teva Pharmaceutical Industries Limited (TEVA) at 9.18%. This indicates that ALNY's price experiences larger fluctuations and is considered to be riskier than TEVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ALNY | TEVA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.94% | 9.18% | +0.76% |
Volatility (6M)Calculated over the trailing 6-month period | 26.34% | 23.54% | +2.80% |
Volatility (1Y)Calculated over the trailing 1-year period | 36.87% | 38.97% | -2.10% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 48.88% | 42.94% | +5.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 53.66% | 47.34% | +6.32% |
Dividends
ALNY vs. TEVA - Dividend Comparison
Neither ALNY nor TEVA has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TEVA Teva Pharmaceutical Industries Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
Financials
ALNY vs. TEVA - Financials Comparison
This section allows you to compare key financial metrics between Alnylam Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ALNY vs. TEVA - Profitability Comparison
ALNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 1.17B. Therefore, the gross margin over that period was 0.0%.
TEVA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 1.97B and revenue of 3.98B. Therefore, the gross margin over that period was 49.5%.
ALNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 268.64M and revenue of 1.17B, resulting in an operating margin of 23.0%.
TEVA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported an operating income of 652.00M and revenue of 3.98B, resulting in an operating margin of 16.4%.
ALNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 205.99M and revenue of 1.17B, resulting in a net margin of 17.7%.
TEVA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a net income of 369.00M and revenue of 3.98B, resulting in a net margin of 9.3%.
Frequently Asked Questions
ALNY and TEVA have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALNY has higher volatility (9.94%) compared to TEVA (9.18%). In terms of maximum drawdown, ALNY dropped -83.58% vs TEVA's -90.89%.
TEVA currently has the higher Sharpe Ratio (2.25 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ALNY and TEVA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer